NSTE-ACS (NSTEMI and UA), Stable Angina (SA), STEMI (STE-ACS)
Conditions
Brief summary
The objective of this study is to determine utilisation patterns in patients receiving Angiox® in participating European centres. Additionally, through the collection of descriptive safety and outcomes data, this study will contribute to the Risk Management strategy for Europe
Interventions
None listed
Sponsors
The Medicines Company
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Eligible for, and receive treatment with Angiox®. * Willing and able to provide written informed consent to the use of their data in accordance with relevant local Data Protection laws, policies and regulations
Exclusion criteria
* Participation in other interventional clinical research studies involving the evaluation of investigational drugs, including Angiox®, or devices at the time of enrolment. * Patients not eligible for treatment for Angiox®.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Posology and usage patterns of Angiox®: Dose(s) and time of bolus and infusion administered | from hospital admission until hospital discharge, or 7 days after administration (which ever is earlier). |
Secondary
| Measure | Time frame |
|---|---|
| Death Myocardial infarction Unplanned revascularisation Stroke Major* and minor bleeding Thrombocytopenia Stent thrombosis Adverse events and serious adverse events | measured in-hospital (prior to discharge), and at post-hospital discharge in outpatient as per local practice (30 days) |
Countries
France, Germany
Outcome results
None listed